FDA Approves First Dual-AAV Gene Therapy for Genetic Hearing Loss Under Priority Voucher Program
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy.
Read the full articleYou might also wanna read
OTARMENI™ (lunsotogene parvec-cwha) suspension, for intracochlear infusion
💡What is OTARMENI? ➡️It is a prescription #genetherapy for children & adults with severe‑to‑profound hearing loss caused by confirmed biall
otarmeni.com·15d agoEuropean Commission Expands Approval of Novartis Gene Therapy for Broader SMA Population
As reported on Pharmaceutical Technology, the European Commission has approved Novartis’ gene replacement therapy Itvisma (onasemnogene abep
AAV gene therapy for homozygous familial hypercholesterolemia: a phase 1 trial
Phase 1 trial shows AAV gene therapy expresses LDLR in liver, reducing LDL-C levels in HoFH. Promising step for 80% HoFH cases. PMID:4224354
FDA Authorizes AirPods Pro as First Over-the-Counter Hearing Aid for Mild to Moderate Hearing Loss
AirPods Pro are now an FDA cleared hearing aid for mild to moderate hearing loss. Here's how the feature works and what it can do for you
womansworld.com·11d ago
FDA Clears NIH-Supported Gene Therapy MMA-101 for First Human Trial in Rare Metabolic Disorder
MMA-101, an NIH-supported gene therapy for a rare metabolic disorder, has received FDA clearance to begin clinical testing.
ncats.nih.gov·17d ago
FDA Drug Approval Affects Healthcare Around the World, but Political Shortcuts Could Hurt the Agency’s International Reputation
The FDA approves the first gene therapy for young children with sickle cell disease, with potential global benefits for healthcare and drug
Comments
Sign in to join the conversation.
No comments yet. Be the first.